---
document_datetime: 2025-12-02 05:01:01
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/dasatinib-accord-healthcare.html
document_name: dasatinib-accord-healthcare.html
version: success
processing_time: 0.121711
conversion_datetime: 2025-12-26 11:44:59.27721
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Dasatinib Accord Healthcare

[RSS](/en/individual-human-medicine.xml/243387)

##### Authorised

This medicine is authorised for use in the European Union

dasatinib Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Dasatinib Accord Healthcare](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-78709)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Dasatinib Accord Healthcare is a cancer medicine. It is used to treat adults with the following types of leukaemia (cancer of the white blood cells):

- chronic myeloid leukaemia (CML) in the 'chronic' phase in newly diagnosed patients who are 'Philadelphia chromosome positive' (Ph+). In CML, granulocytes (a type of white blood cell) start growing out of control. Ph+ means that some of the patient's genes have rearranged themselves to form a special chromosome called the Philadelphia chromosome which produces an enzyme, Bcr-Abl kinase that leads to the development of leukaemia.
- CML in 'chronic', 'accelerated' and 'blast' phases. Dasatinib Accord Healthcare is used when other treatments including imatinib (another cancer medicine) do not work or cause troublesome side effects;
- Ph+ acute lymphoblastic leukaemia (ALL), where lymphocytes (another type of white blood cell) multiply too quickly, or in 'lymphoid blast' CML. Dasatinib Accord Healthcare is used when other treatments do not work or cause troublesome side effects.

Dasatinib Accord Healthcare is also used in children to treat:

- newly diagnosed Ph+ CML in the 'chronic' phase, or Ph+ CML when other treatments including imatinib cannot be given or have not worked;
- newly diagnosed Ph+ ALL in combination with chemotherapy (cancer medicines).

Dasatinib Accord Healthcare contains the active substance dasatinib and is a 'generic medicine'. This means that Dasatinib Accord Healthcare contains the same active substance and works in the same way as a 'reference medicine' already authorised in the EU. The reference medicine for Dasatinib Accord Healthcare is Sprycel. For more information on generic medicines, see the question-and-answer document [here](https://www.ema.europa.eu/en/documents/other/questions-and-answers-generic-medicines_en.pdf) .

Expand section

Collapse section

## How is Dasatinib Accord Healthcare used?

Dasatinib Accord Healthcare can only be obtained with a prescription and treatment should be started by a doctor who has experience in the diagnosis and treatment of leukaemia.

Dasatinib Accord Healthcare is available as tablets to be taken by mouth. It is taken once a day, consistently either in the morning or in the evening.

The starting dose depends on the condition being treated and, for children, their body weight. The dose is then gradually increased until the disease is controlled well enough. In children with ALL who are also receiving other cancer medicines, a fixed dose of Dasatinib Accord Healthcare is used throughout their treatment. The doctor may reduce the dose or interrupt treatment if blood cell counts are too low or certain side effects occur. Treatment is stopped if the medicine no longer controls the condition or if the patient cannot take the medicine because of side effects.

For more information about using Dasatinib Accord Healthcare, see the package leaflet or contact your doctor or pharmacist.

## How does Dasatinib Accord Healthcare work?

The active substance in Dasatinib Accord Healthcare, dasatinib, belongs to a group of medicines that block enzymes known as protein kinases. Dasatinib acts mainly by blocking the BCR-ABL protein kinase. This enzyme is produced by leukaemia cells, and causes them to multiply uncontrollably. By blocking BCR-ABL kinase, as well as other kinases, Dasatinib Accord Healthcare helps to reduce the number of leukaemia cells.

## How has Dasatinib Accord Healthcare been studied?

Studies on the benefits and risks of the active substance in the authorised uses have already been carried out with the reference medicine, Sprycel, and do not need to be repeated for Dasatinib Accord Healthcare.

As for every medicine, the company provided studies on the quality of Dasatinib Accord Healthcare. The company also carried out a study that showed that it is 'bioequivalent' to the reference medicine. Two medicines are bioequivalent when they produce the same levels of the active substance in the body and are therefore expected to have the same effect.

## What are the benefits and risks of Dasatinib Accord Healthcare?

Because Dasatinib Accord Healthcare is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.

## Why is Dasatinib Accord Healthcare authorised in the EU?

The European Medicines Agency concluded that, in accordance with EU requirements, Dasatinib Accord Healthcare has been shown to have comparable quality and to be bioequivalent to Sprycel. Therefore, the Agency's view was that, as for Sprycel, the benefits of Dasatinib Accord Healthcare outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Dasatinib Accord Healthcare?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Dasatinib Accord Healthcare have been included in the summary of product characteristics and the package leaflet. Any additional measures in place for Sprycel also apply to Dasatinib Accord Healthcare where appropriate.

As for all medicines, data on the use of Dasatinib Accord Healthcare are continuously monitored. Suspected side effects reported with Dasatinib Accord Healthcare are carefully evaluated and any necessary action taken to protect patients.

## Other information about Dasatinib Accord Healthcare

Dasatinib Accord Healthcare received a marketing authorisation valid throughout the EU on 26 July 2024.

Dasatinib Accord Healthcare : EPAR - Medicine overview

Reference Number: EMA/317632/2024

English (EN) (161.76 KB - PDF)

**First published:** 01/08/2024

[View](/en/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-696)

български (BG) (176.94 KB - PDF)

**First published:**

21/08/2024

[View](/bg/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_bg.pdf)

español (ES) (152.63 KB - PDF)

**First published:**

21/08/2024

[View](/es/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_es.pdf)

čeština (CS) (173.61 KB - PDF)

**First published:**

21/08/2024

[View](/cs/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_cs.pdf)

dansk (DA) (151.6 KB - PDF)

**First published:**

21/08/2024

[View](/da/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_da.pdf)

Deutsch (DE) (155.46 KB - PDF)

**First published:**

21/08/2024

[View](/de/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_de.pdf)

eesti keel (ET) (150.2 KB - PDF)

**First published:**

21/08/2024

[View](/et/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_et.pdf)

ελληνικά (EL) (178.45 KB - PDF)

**First published:**

21/08/2024

[View](/el/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_el.pdf)

français (FR) (154.02 KB - PDF)

**First published:**

21/08/2024

[View](/fr/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_fr.pdf)

hrvatski (HR) (172.85 KB - PDF)

**First published:**

21/08/2024

[View](/hr/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_hr.pdf)

italiano (IT) (151.38 KB - PDF)

**First published:**

21/08/2024

[View](/it/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (183.8 KB - PDF)

**First published:**

21/08/2024

[View](/lv/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (173.89 KB - PDF)

**First published:**

21/08/2024

[View](/lt/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_lt.pdf)

magyar (HU) (174.61 KB - PDF)

**First published:**

21/08/2024

[View](/hu/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_hu.pdf)

Malti (MT) (175.38 KB - PDF)

**First published:**

21/08/2024

[View](/mt/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_mt.pdf)

Nederlands (NL) (152.76 KB - PDF)

**First published:**

21/08/2024

[View](/nl/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_nl.pdf)

polski (PL) (177.6 KB - PDF)

**First published:**

21/08/2024

[View](/pl/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_pl.pdf)

português (PT) (153.32 KB - PDF)

**First published:**

21/08/2024

[View](/pt/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_pt.pdf)

română (RO) (171.47 KB - PDF)

**First published:**

21/08/2024

[View](/ro/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_ro.pdf)

slovenčina (SK) (173.77 KB - PDF)

**First published:**

21/08/2024

[View](/sk/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_sk.pdf)

slovenščina (SL) (172.63 KB - PDF)

**First published:**

21/08/2024

[View](/sl/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_sl.pdf)

Suomi (FI) (150.57 KB - PDF)

**First published:**

21/08/2024

[View](/fi/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_fi.pdf)

svenska (SV) (151.48 KB - PDF)

**First published:**

21/08/2024

[View](/sv/documents/overview/dasatinib-accord-healthcare-epar-medicine-overview_sv.pdf)

Dasatinib Accord Healthcare : EPAR - Risk management plan

English (EN) (335.62 KB - PDF)

**First published:** 01/08/2024

**Last updated:** 13/11/2025

[View](/en/documents/rmp/dasatinib-accord-healthcare-epar-risk-management-plan_en.pdf)

## Product information

Dasatinib Accord Healthcare : EPAR - Product information

English (EN) (594.28 KB - PDF)

**First published:** 01/08/2024

**Last updated:** 21/08/2025

[View](/en/documents/product-information/dasatinib-accord-healthcare-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-665)

български (BG) (750.33 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/bg/documents/product-information/dasatinib-accord-healthcare-epar-product-information_bg.pdf)

español (ES) (581.75 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/es/documents/product-information/dasatinib-accord-healthcare-epar-product-information_es.pdf)

čeština (CS) (654.81 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/cs/documents/product-information/dasatinib-accord-healthcare-epar-product-information_cs.pdf)

dansk (DA) (612.63 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/da/documents/product-information/dasatinib-accord-healthcare-epar-product-information_da.pdf)

Deutsch (DE) (664.47 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/de/documents/product-information/dasatinib-accord-healthcare-epar-product-information_de.pdf)

eesti keel (ET) (561.59 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/et/documents/product-information/dasatinib-accord-healthcare-epar-product-information_et.pdf)

ελληνικά (EL) (838.48 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/el/documents/product-information/dasatinib-accord-healthcare-epar-product-information_el.pdf)

français (FR) (616.16 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/fr/documents/product-information/dasatinib-accord-healthcare-epar-product-information_fr.pdf)

hrvatski (HR) (693.15 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/hr/documents/product-information/dasatinib-accord-healthcare-epar-product-information_hr.pdf)

íslenska (IS) (586.66 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/is/documents/product-information/dasatinib-accord-healthcare-epar-product-information_is.pdf)

italiano (IT) (601.45 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/it/documents/product-information/dasatinib-accord-healthcare-epar-product-information_it.pdf)

latviešu valoda (LV) (694.83 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/lv/documents/product-information/dasatinib-accord-healthcare-epar-product-information_lv.pdf)

lietuvių kalba (LT) (660.78 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/lt/documents/product-information/dasatinib-accord-healthcare-epar-product-information_lt.pdf)

magyar (HU) (811.21 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/hu/documents/product-information/dasatinib-accord-healthcare-epar-product-information_hu.pdf)

Malti (MT) (754.08 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/mt/documents/product-information/dasatinib-accord-healthcare-epar-product-information_mt.pdf)

Nederlands (NL) (591.55 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/nl/documents/product-information/dasatinib-accord-healthcare-epar-product-information_nl.pdf)

norsk (NO) (610.32 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/no/documents/product-information/dasatinib-accord-healthcare-epar-product-information_no.pdf)

polski (PL) (668.25 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/pl/documents/product-information/dasatinib-accord-healthcare-epar-product-information_pl.pdf)

português (PT) (546.73 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/pt/documents/product-information/dasatinib-accord-healthcare-epar-product-information_pt.pdf)

română (RO) (750.79 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/ro/documents/product-information/dasatinib-accord-healthcare-epar-product-information_ro.pdf)

slovenčina (SK) (706.19 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sk/documents/product-information/dasatinib-accord-healthcare-epar-product-information_sk.pdf)

slovenščina (SL) (700.49 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sl/documents/product-information/dasatinib-accord-healthcare-epar-product-information_sl.pdf)

Suomi (FI) (604.7 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/fi/documents/product-information/dasatinib-accord-healthcare-epar-product-information_fi.pdf)

svenska (SV) (650.04 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sv/documents/product-information/dasatinib-accord-healthcare-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000288694 19/08/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Dasatinib Accord Healthcare : EPAR - All authorised presentations

English (EN) (40.41 KB - PDF)

**First published:** 01/08/2024

**Last updated:** 21/08/2025

[View](/en/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-512)

български (BG) (74.98 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/bg/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_bg.pdf)

español (ES) (40.81 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/es/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_es.pdf)

čeština (CS) (52.66 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/cs/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (43.2 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/da/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (40.48 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/de/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (43.6 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/et/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (82.87 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/el/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_el.pdf)

français (FR) (50.89 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/fr/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (62.03 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/hr/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (43.59 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/is/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_is.pdf)

italiano (IT) (40.52 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/it/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (65.09 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/lv/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (68.41 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/lt/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (67 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/hu/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (66.27 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/mt/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (43 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/nl/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (46.31 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/no/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_no.pdf)

polski (PL) (57.93 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/pl/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_pl.pdf)

português (PT) (50.11 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/pt/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_pt.pdf)

română (RO) (66.42 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/ro/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (53.02 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sk/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (48.86 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sl/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (41.71 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/fi/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (42.98 KB - PDF)

**First published:**

01/08/2024

**Last updated:**

21/08/2025

[View](/sv/documents/all-authorised-presentations/dasatinib-accord-healthcare-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Dasatinib Accord Healthcare Active substance Dasatinib monohydrate International non-proprietary name (INN) or common name dasatinib Therapeutic area (MeSH)

- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Anatomical therapeutic chemical (ATC) code L01EA02

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Dasatinib Accord Healthcare is indicated for the treatment of adult patients with:

- newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
- chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib.
- Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

Dasatinib Accord Healthcare is indicated for the treatment of paediatric patients with:

- newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.
- newly diagnosed Ph+ ALL in combination with chemotherapy.

## Authorisation details

EMA product number EMEA/H/C/006251

Generic

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see [Generic and hybrid medicines](/node/69107) .

Marketing authorisation holder

Accord Healthcare S.L.U.

Edificio Este Planta 6a

Opinion adopted 30/05/2024 Marketing authorisation issued 26/07/2024 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Dasatinib Accord Healthcare : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (143.57 KB - PDF)

**First published:** 21/08/2025

**Last updated:** 13/11/2025

[View](/en/documents/procedural-steps-after/dasatinib-accord-healthcare-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Dasatinib Accord Healthcare : EPAR - Public assessment report

Adopted

Reference Number: EMA/313181/2024

English (EN) (894.02 KB - PDF)

**First published:** 01/08/2024

[View](/en/documents/assessment-report/dasatinib-accord-healthcare-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Dasatinib Accord Healthcare

Reference Number: EMA/CHMP/233375/2024

English (EN) (160.2 KB - PDF)

**First published:** 31/05/2024

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-dasatinib-accord-healthcare_en.pdf)

#### News on Dasatinib Accord Healthcare

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 May 2024](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-may-2024) 31/05/2024

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Dasatinib Accord Healthcare : EPAR - Product information - tracked changes

English (EN) (334.84 KB - DOCX)

**First published:** 21/08/2025

[View](/en/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-320)

български (BG) (271.62 KB - DOCX)

**First published:**

21/08/2025

[View](/bg/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_bg.docx)

español (ES) (297.04 KB - DOCX)

**First published:**

21/08/2025

[View](/es/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_es.docx)

čeština (CS) (400.73 KB - DOCX)

**First published:**

21/08/2025

[View](/cs/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (392.74 KB - DOCX)

**First published:**

21/08/2025

[View](/da/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (411.84 KB - DOCX)

**First published:**

21/08/2025

[View](/de/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (364.04 KB - DOCX)

**First published:**

21/08/2025

[View](/et/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (362.29 KB - DOCX)

**First published:**

21/08/2025

[View](/el/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_el.docx)

français (FR) (380 KB - DOCX)

**First published:**

21/08/2025

[View](/fr/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (373.1 KB - DOCX)

**First published:**

21/08/2025

[View](/hr/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (337.77 KB - DOCX)

**First published:**

21/08/2025

[View](/is/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_is.docx)

italiano (IT) (329.34 KB - DOCX)

**First published:**

21/08/2025

[View](/it/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (295.15 KB - DOCX)

**First published:**

21/08/2025

[View](/lv/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (274.85 KB - DOCX)

**First published:**

21/08/2025

[View](/lt/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (394.38 KB - DOCX)

**First published:**

21/08/2025

[View](/hu/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (379.31 KB - DOCX)

**First published:**

21/08/2025

[View](/mt/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (319.36 KB - DOCX)

**First published:**

21/08/2025

[View](/nl/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (395.46 KB - DOCX)

**First published:**

21/08/2025

[View](/no/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_no.docx)

polski (PL) (282.44 KB - DOCX)

**First published:**

21/08/2025

[View](/pl/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_pl.docx)

português (PT) (262.8 KB - DOCX)

**First published:**

21/08/2025

[View](/pt/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_pt.docx)

română (RO) (325.79 KB - DOCX)

**First published:**

21/08/2025

[View](/ro/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (271.64 KB - DOCX)

**First published:**

21/08/2025

[View](/sk/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (336.37 KB - DOCX)

**First published:**

21/08/2025

[View](/sl/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (279.2 KB - DOCX)

**First published:**

21/08/2025

[View](/fi/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (382.61 KB - DOCX)

**First published:**

21/08/2025

[View](/sv/documents/product-information-tracked-changes/dasatinib-accord-healthcare-epar-product-information-tracked-changes_sv.docx)

**This page was last updated on** 13/11/2025

## Share this page

[Back to top](#main-content)